CanSino latest to file for HKEX IPO

Vaccines company CanSino Biologics Inc. (Tianjin, China) on July 17 proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley and CLSA.

CanSino said in its prospectus that it expects to submit NDAs in China for MCV4, a quadrivalent meningococcal conjugate vaccine, by year end as well as for MCV2, a bivalent meningococcal conjugate vaccine, MCV2 -- next year. The company's Ad5-EBOV, a recombinant human adenovirus type 5 vector based vaccine expression Ebola virus glycoprotein, is approved in China to treat Ebola virus infection...